KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Inventory (2016 - 2025)

Historic Inventory for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $176.5 million.

  • Halozyme Therapeutics' Inventory rose 2440.08% to $176.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $176.5 million, marking a year-over-year increase of 2440.08%. This contributed to the annual value of $176.5 million for FY2025, which is 2440.08% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Inventory of $176.5 million as of Q4 2025, which was up 2440.08% from $185.8 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Inventory registered a high of $185.8 million during Q3 2025, and its lowest value of $47.8 million during Q1 2022.
  • Its 5-year average for Inventory is $119.1 million, with a median of $128.3 million in 2023.
  • Per our database at Business Quant, Halozyme Therapeutics' Inventory plummeted by 1813.76% in 2022 and then soared by 12512.3% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Inventory stood at $53.9 million in 2021, then surged by 85.73% to $100.1 million in 2022, then rose by 27.44% to $127.6 million in 2023, then rose by 11.17% to $141.9 million in 2024, then grew by 24.4% to $176.5 million in 2025.
  • Its Inventory was $176.5 million in Q4 2025, compared to $185.8 million in Q3 2025 and $181.5 million in Q2 2025.